This is a randomized, double-blind, parallel group, placebo-controlled, dose optimized, phase 3 study to evaluate the safety and efficacy of PRC-063 in the treatment of ADHD in adults
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
288
Daily dose
Daily dose
Meridien Research Inc.
Bradenton, Florida, United States
Meridien Research
Lakeland, Florida, United States
Meridien Research Inc.
Maitland, Florida, United States
South Shore Psychiatric Services
Hingham, Massachusetts, United States
Post-dose PERMP-T (Permanent Measure of Productivity - Total Score) Scores Measured During the Full-day Adult Laboratory Classroom Visit
PERMP-T measures the number of completed and number of attempted math problems completed during a 10 minute test. The scale ranges from 0 to 800, with a higher score indicating a better outcome.
Time frame: Full-day ALC - 13 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Center for Psychiatry and Behavioral Medicine
Las Vegas, Nevada, United States
Center for Psychiatry and Behavioral Medicine
Durham, North Carolina, United States
Penn State Health Milton S. Hershey Medical Center
Hershey, Pennsylvania, United States
Bayou City Research
Houston, Texas, United States